FT. MYERS, Fla., Feb. 27 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) announced today that it has received a laboratory license for its new Irvine, California laboratory location and has received certification for this laboratory under the Clinical Laboratory Improvement Act, as amended (CLIA) through inspection by the California Department of Health.
NeoGenomics President, Robert Gasparini, said, “I am delighted to report that as a result of obtaining our license, we can now commence revenue operations at this facility. Revenues will start out modest as we continue to hire staff for this location, but, over time, we believe that California and the surrounding markets will be substantial contributors to our revenue and earnings growth. As cancer is primarily a disease of the elderly, the cancer genetics industry tends to do very well in areas where there are high concentrations of senior citizens. Indeed, the marketplace in southern California is similar in many respects to the marketplace in southern Florida, where NeoGenomics already has a substantial presence. We are excited to bring our industry-leading turn-around-times to the oncologists, urologists, pathologists and hospitals in this market and are hopeful that our services will be as warmly received in California as they have been in all of our other locations.”
In other news, NeoGenomics also announced that it would release its final Q4 FY 2006 and full year earnings on Wednesday, March 14, 2007. The Company has also scheduled a web-cast and conference call to discuss these results on March 14th, at 11:00 AM EST to discuss these results. Interested investors should dial (877) 407-0778 (domestic) and (201) 689-8565 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on March 28, 2007 and can be accessed by dialing (877) 660-6853 (domestic) and (201) 612-7415 (international). The playback account number is 286 and the playback conference ID#/PIN# is 233199. The web-cast may be accessed under the Investor Relations section of the NeoGenomics website at http://www.neogenomics.org or at the website of our Investor Relations firm, Hawk Associates, at http://www.hawkassociates.com/ngnmmore.aspx or at http://www.vcall.com/IC/CEPage.asp?ID=114420. An archive of the web-cast will be available until 11:59 PM EST on June 11, 2007.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
Interested parties can also access additional investor relations material, including an in-depth equity research report, from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/ or from Hawk Associates at http://www.hawkassociates.com. An investment profile about NeoGenomics may be found at http://www.hawkassociates.com/ngnmprofile.aspx.
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company’s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company’s periodic filings with the SEC.
Source: NeoGenomics, Inc.
